Collegium Pharmaceutical, Inc. COLL Durham, North Carolina — Impairment expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseImpairmentLoss.
The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:34 AM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-011992
In connection with the Ironshore Acquisition, the Company acquired an operating lease for the former U.S. headquarters of Ironshore pursuant to which the Company leases 8,817 of rentable square feet of space in Durham, North Carolina (the “Ironshore Lease”). The Ironshore Lease continues through February 2028. In the year ended December 31, 2025, the Company concluded that the right-of-use asset associated with the Ironshore Lease was impaired, and the Company recognized an impairment expense of $575 within selling, operating and administrative expense.
Item 16. Form 10-K Summary
FAQ
- What is Collegium Pharmaceutical, Inc.'s durham, north carolina — impairment expense?
- Collegium Pharmaceutical, Inc. (COLL) reported durham, north carolina — impairment expense of $143.75K in Q4 2025.
- What does durham, north carolina — impairment expense mean?
- This metric represents the non-cash charge recognized when the carrying value of long-lived assets or intangible assets associated with the Durham, North Carolina segment exceeds their fair market value. An increase in this expense indicates a decline in the expected future economic benefit of assets located in this region, often signaling operational challenges or strategic shifts. Monitoring this figure is critical for assessing asset quality and the potential for future write-downs in specific geographic segments.
Ask your AI about Collegium Pharmaceutical, Inc.'s durham, north carolina — impairment expense.
Connect your AI assistant and compare it to peers, right in your chat.
